Josh Reisberg outlines the foundation of a broad, overall defense strategy for generic companies embroiled in Hatch-Waxman patent infringement litigations.
Josh Reisberg
Advertisement
Josh Reisberg is counsel at Axinn Veltrop & Harkrider LLP (New York, NY).
Articles by Josh Reisberg
Advertisement
Latest Updated Articles
Beyond the Merits: Generic Company Defense StrategiesPublished: June 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
